2 hours ago · Metsera Inc. raised $275 million in its IPO, selling 15.3 million shares for $18 each, according to a statement Bloomberg Terminal It had offered 17.2 million shares for $15 to $17 each.

3 days ago · Metsera, which is developing weight-loss drugs, said on Monday it is seeking a valuation of up to $1.78 billion in its U.S. IPO, aiming to capitalize on Wall Street's insatiable appetite for such ...

1 day ago · Metsera and Maze Therapeutics are the second and third biotechnology firms this year to go public, raising $275 million and $140 million, respectively, in a pair of new stock offerings priced Thursday. Metsera shares will trade on the Nasdaq Friday under the symbol “MTSR,” while Maze’s stock ...

2 days ago · US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape in 2025. Metsera is offering over 17 million shares priced between $15 and $17 for its Nasdaq listing. The biotech is targeting $250.8m based on the midpoint of the price ...

3 hours ago · In addition, Metsera has granted the underwriters a 30-day option to purchase up to an additional 2,291,666 shares of common stock at the initial public offering price less underwriting discounts ...

3 days ago · This morning also saw Maze Therapeutics outline plans for a $131 million IPO, while Hong Kong-listed Ascentage Pharma joined the Nasdaq via a $126.4 million offering on Friday.. Metsera plans to ...

2 days ago · Metsera intends to raise $275 million in gross proceeds from an IPO of its common stock, offering approximately 17.19 million shares at a proposed midpoint price of $16.00 per share.